CDEK
← All drugs Report issue

Abagovomab

mAbexperimental

Clinical trial activity

3 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Dec 1, 2002 (NCT00058435)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • Mucin-16OTHER

    MUC16 other

    It does not bind directly to CA-125, but it works as a "surrogate" antigen, enabling the immune system to identify and attack tumour cells displaying the CA-125 protein.

  • Mucin-16Immunity, passive

    MUC16 immunity, passive

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • abagovomab
  • abagovomab
  • aca 125
  • aca 125
  • aca-125
  • men-2234

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00418574Phase 2/Phase 3 (Phase 3)Dec 1, 2006AGO Germany, Cornell University, Menarini Group, Stanford University, Universita' Cattolica del Sacro Cuore
NCT00103545Phase 1/Phase 2 (Phase 2)Jul 1, 2003AGO Germany
NCT00058435Phase 1Dec 1, 2002Cornell University, National Cancer Institute (NCI)
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AGO GermanyAcademic/Hospital2122003
Cornell UniversityAcademic/Hospital2122002
Menarini GroupFor profit1112006
National Cancer Institute (NCI)Government1012002
Stanford UniversityAcademic/Hospital1012006
Universita' Cattolica del Sacro CuoreAcademic/Hospital1012006
6 organizations
Page 1 / 1